<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110201796800473936311.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260406/6391110201796800473936311.jpeg"/>
Leidi Network, April 6
FOSUN PHARMA (stock code: 600196) recently announced that the board of directors received a written resignation letter from Chen Zhanyu, who applied to resign from the position of Chief Financial Officer due to adjustments in work arrangements. The resignation is effective from April 2, 2026.
After the resignation takes effect, Chen Zhanyu will continue to serve as the company's Senior Vice President. On April 2, 2026, upon the nomination of the company's Chief Executive Officer, the board of directors agreed to appoint Huang Zhi as the company's Senior Vice President and Chief Financial Officer, with a term starting from April 2, 2026, until the end of the current board's term.
Huang Zhi, a permanent resident of the United States, joined FOSUN PHARMA (including FOSUN PHARMA and its holding subsidiaries/units, hereinafter the same) in February 2026 and currently serves as the company's Senior Vice President, Chief Financial Officer, and Co-President of the Innovative Drug Division.
Before joining the group, Huang Zhi mainly engaged in finance-related work. From April 2007 to October 2020, he held various positions at Novartis AG (stock code: NVS.NYS), listed on the New York Stock Exchange, including Business Planning Analysis Manager for the U.S. Oncology Division, Financial Head for West China, Head of Business Processes and Controls for Greater China, Head of Business Planning and Analysis for Greater China, and Chief Financial Officer for South Korea.
From October 2020 to February 2025, Huang Zhi served as Chief Financial Officer for Greater China at BeOne Medicines, Financial Head for the Asia-Pacific region (excluding China), Global Technology Operations Financial Head, and Financial Head of the Innovation Center. During this period, he served as Global Commercial Finance Head for BeOne Medicines from June 2023 to February 2025.
From May 2025 to January 2026, Huang Zhi served as Senior Vice President of Global Corporate Development &amp; Finance at Ascentage Pharma (stock code: 6855.HK, AAPG.NASDAQ).
———————————————

600196

159929

588130

FOSUN PHARMA announced that CFO Chen Zhanyu resigned due to adjustments in work arrangements, effective April 2, 2026, and will continue to serve as Senior Vice President after resignation. Huang Zhi will take over as CFO, starting from April 2, 2026. Huang Zhi joined FOSUN PHARMA in February 2026 and has held finance-related positions at BeOne Medicines and Novartis

雷帝触网

FOSUN PHARMA

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

BeOne Medicines

China Merchants CSI Biotechnology Theme ETF

BEONE MEDICINES

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

FOSUN PHARMA CFO Chen Zhanyu resigns, former BeOne Medicines executive Huang Zhi takes over